卡培他滨联合多西他赛治疗晚期三阴性乳腺癌的临床效果观察

Clinical observation of capecitabine combined with docetaxel in the treatment of advanced triplenegative breast cancer

目的 分析卡培他滨联合多西他赛治疗晚期三阴性乳腺癌(TNBC)患者的临床疗效。方法 90例晚期TNBC患者,按照1︰1比例法分为对照组和观察组,各45例。对照组患者采取顺铂+多西他赛治疗,观察组患者采取卡培他滨+多西他赛治疗,比较两组晚期TNBC患者治疗效果与安全性、免疫功能指标[免疫球蛋白(Ig)G、IgM、IgA]、生活质量(生理状况、功能状况)评分。结果 治疗后,观察组患者总有效率86.67%高于对照组的60.00%,差异有统计学意义(P<0.05);观察组恶心呕吐、白细胞减少、手足综合征不良反应发生率分别为33.33%、24.44%、11.11%,与对照组的35.56%、24.44%、15.56%比较,差异无统计学意义(P>0.05)。治疗后,观察组患者IgG、IgM、IgA分别为(12.50±1.25)、(1.15±0.12)、(2.50±0.20)g/L,高于对照组的(9.80±0.99)、(0.85±0.10)、(1.60±0.10)g/L,生理状况、功能状况评分分别为(1.05±0.40)、(1.03±0.50)分,低于对照组的(1.90±0.60)、(1.85±0.55)分,差异有统计学意义(P<0.05)。结论 晚期TNBC行卡培他滨联合多西他赛治疗效果显著、安全性理想,可以有效降低体内免疫抑制水平,患者预后良好,提升生活质量,值得临床推广应用。

Objective To analyze the clinical efficacy of capecitabine combined with docetaxel in the treatment of advanced triple-negative breast cancer (TNBC).Methods A total of 90 patients with advanced TNBC were divided into the control group and the observation group according to the ratio of 1︰1,with45 cases in each group.Patients in the control group were treated with cisplatin and docetaxel,and patients in the observation group were treated with capecitabine and docetaxel.The therapeutic effect,safety,immune function indicators[immunoglobulin (Ig)G,IgM,IgA],and quality of life (physiological status,functional status)scorewere compared between the two groups.Results After treatment,the total effective rate of the observation group was 86.67%,which was higher than 60.00%of the control group,and the difference was statistically significant (P<0.05).The incidence of nausea and vomiting,leukopenia,hand-foot syndrome of the observation group were 33.33%,24.44%and 11.11%,which were not statistically significant compared with 35.56%,24.44%and 15.56%of the control group (P>0.05).After treatment,the IgG (12.50±1.25) g/L,IgM (1.15±0.12) g/L and IgA (2.50±0.20) g/L of the observation group were higher than (9.80±0.99),(0.85±0.10),and (1.60±0.10) g/L of the control group,and the physiological status score (1.05±0.40) points and functional status score (1.03±0.50) points were lower than (1.90±0.60) and (1.85±0.55) points of the control group.All the differences were statistically significant (P<0.05).Conclusion The combination of capecitabine and docetaxel is safe and effective for advanced TNBC,and can effectively reduce the level of immunosuppression in the body,improve the prognosis of patients and enhance the quality of life,which is worthy of clinical promotion and application.